Sexual Health Research//Research Reference

PT-141 (Bremelanotide)

Melanocortin receptor agonist; bremelanotide is the active ingredient of the FDA-approved drug Vyleesi for premenopausal HSDD, distinct from research-grade PT-141.

Technical Dossier

Batch / Lot Number

—

Testing Status

—

Testing Laboratory

—

Test Date

—

Classification

Melanocortin receptor agonist (cyclic peptide); active ingredient of Vyleesi

Mechanism / Biological Target

Activates melanocortin receptors (principally MC4R) in the hypothalamus; animal studies implicate presynaptic MC4R activation in the medial preoptic area in the modulation of sexual desire.

Research Areas

Sexual HealthNeuroendocrinology

Research Overview

Bremelanotide (PT-141) is a cyclic melanocortin receptor agonist. The FDA approved bremelanotide (brand Vyleesi) in 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on phase 3 trials showing improved desire and reduced distress. This entry is a research-reference summary only; the approved pharmaceutical product (Vyleesi) is distinct from research-grade PT-141 material and is not represented or offered by this catalog entry. No clinical-use instructions are provided.

Laboratory Storage & Handling

For laboratory/research material only. Store lyophilized material desiccated at -20°C, protected from light and moisture. Avoid repeated freeze-thaw cycles. Handle using appropriate laboratory PPE and follow institutional SOPs. Not for human administration, reconstitution for human use, or diagnostic use.

References

Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
Mayer D, Lynch SE. Annals of Pharmacotherapy, 2020.
An effect on the subjective sexual response in premenopausal women by Bremelanotide (PT-141), a melanocortin receptor agonist
Diamond LE, et al. Journal of Sexual Medicine, 2006.
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Molinoff PB, et al. Annals of the NY Academy of Sciences, 2003.
Bremelanotide (FDA approval 2019; LiverTox record)
NCBI Bookshelf / LiverTox, 2019.

Available Documentation

Certificate of AnalysisPending / Not yet available

For Research Use Only

Compounds referenced on Peptide Underground are intended for laboratory and research purposes only. They are not intended to diagnose, treat, cure, or prevent any disease and are not intended for human consumption.